Form 4: Sarepta CFO's Routine Tax-Related Stock Disposition

Sarepta Therapeutics' CFO, Ryan Ho-Yan Wong, reported a disposition of 256 common shares to cover tax obligations related to RSU vesting.

Summary

• Ryan Ho-Yan Wong, Chief Financial Officer of Sarepta Therapeutics, Inc. (SRPT), reported a transaction involving the company's common stock.
• The transaction, dated March 11, 2026, was a disposition of 256 shares of common stock.
• These shares were withheld by Sarepta Therapeutics to satisfy tax withholding obligations.
• The tax withholding was related to the vesting of restricted stock units (RSUs) that were granted on March 10, 2025.
• The price per share for the disposition was $17.03.
• Following this reported transaction, Mr. Wong beneficially owns 135,064 shares of Sarepta Therapeutics common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative transaction for tax purposes, not indicative of positive or negative sentiment regarding the company's performance or future.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that tax-related dispositions of shares following restricted stock unit (RSU) vesting are common and routine for executives. This type of transaction is a standard part of executive compensation plans and typically does not reflect a change in management's outlook on the company's prospects or operational performance.

Related Party Transactions

• Disposition of 256 common shares to Sarepta Therapeutics, Inc. to satisfy tax withholding obligations related to RSU vesting, a common related-party interaction in executive compensation.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine tax-related transaction and not a discretionary market sale, with negligible effect on outstanding share count.

Key Dates

Recommendation

This Form 4 reports a routine disposition of shares by an executive to cover tax obligations upon the vesting of restricted stock units. Such transactions are administrative in nature and do not typically signal a change in the company's fundamentals or the executive's confidence, thus not warranting a change in investment recommendation based solely on this filing.

Keywords

Sarepta Therapeutics, SRPT, Form 4, Insider Transaction, CFO, Ryan Ho-Yan Wong, Restricted Stock Units, RSU, Tax Withholding